{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T23:32:01Z","timestamp":1789687921500,"version":"4.0.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2007,2,24]],"date-time":"2007-02-24T00:00:00Z","timestamp":1172275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2007,2,24]],"date-time":"2007-02-24T00:00:00Z","timestamp":1172275200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"published-print":{"date-parts":[[2007,8]]},"DOI":"10.1007\/s11239-007-0017-9","type":"journal-article","created":{"date-parts":[[2007,3,16]],"date-time":"2007-03-16T12:25:15Z","timestamp":1174047915000},"page":"43-51","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Razaxaban, a direct factor Xa inhibitor, in combination with aspirin and\/or clopidogrel improves low-dose antithrombotic activity without enhancing bleeding liability in rabbits"],"prefix":"10.1007","volume":"24","author":[{"given":"Pancras C.","family":"Wong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Earl J.","family":"Crain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol A.","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth R.","family":"Wexler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick Y. S.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mimi L.","family":"Quan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Knabb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,2,24]]},"reference":[{"key":"17_CR1","doi-asserted-by":"publisher","first-page":"137","DOI":"10.2174\/1568026013395407","volume":"1","author":"ML Quan","year":"2001","unstructured":"Quan ML, Wexler RR (2001) The design and synthesis of noncovalent factor Xa inhibitors. Curr Topics Med Chem 1:137\u2013149","journal-title":"Curr Topics Med Chem"},{"key":"17_CR2","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1021\/jm000409z","volume":"44","author":"DJ Pinto","year":"2001","unstructured":"Pinto DJ, Orwat MJ, Wang S et al (2001) Discovery of 1-[3-(aminomethyl)phenyl]-N-3-fluoro-2\u2032-(methylsulfonyl)-[1,1\u2032-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem 44:566\u2013178","journal-title":"J Med Chem"},{"key":"17_CR3","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/j.1527-3466.2002.tb00188.x","volume":"20","author":"PC Wong","year":"2002","unstructured":"Wong PC, Pinto DJ, Knabb RM (2002) Nonpeptide factor Xa inhibitors: DPC423, a highly potent and orally bioavailable pyrazole antithrombotic agent. Cardiovasc Drug Rev 20:137\u2013152","journal-title":"Cardiovasc Drug Rev"},{"key":"17_CR4","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1021\/jm0497949","volume":"48","author":"ML Quan","year":"2005","unstructured":"Quan ML, Lam PY, Han Q et al (2005) Discovery of 1-(3\u2032-aminobenzisoxazol-5\u2032-yl)-3-trifluoromethyl-N-[2-fluoro-4- [(2\u2032-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide hydrochloride (razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor. J Med Chem 48:1729\u20131744","journal-title":"J Med Chem"},{"key":"17_CR5","first-page":"212","volume":"295","author":"PC Wong","year":"2000","unstructured":"Wong PC, Crain EJ, Knabb RM et al (2000) Nonpeptide factor Xa inhibitors: II. antithrombotic evaluation in a rabbit model of electrically induced carotid artery thrombosis. J Pharmacol Exp Ther 295:212\u2013218","journal-title":"J Pharmacol Exp Ther"},{"key":"17_CR6","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1055\/s-2003-40674","volume":"3","author":"M Gawaz","year":"2003","unstructured":"Gawaz M, M\u00fcller I, Besta F (2003) Combined antithrombotic therapy for acute coronary syndrome. Semin Vasc Med 3:163\u2013175","journal-title":"Semin Vasc Med"},{"key":"17_CR7","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1055\/s-2005-916169","volume":"5","author":"L Wallentin","year":"2005","unstructured":"Wallentin L (2005) Prevention of cardiovascular events after acute coronary syndrome. Sem Vasc Med 5:293\u2013300","journal-title":"Sem Vasc Med"},{"key":"17_CR8","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1093\/eurheartj\/ehi485","volume":"27","author":"F Andreotti","year":"2006","unstructured":"Andreotti F, Testa L, Biondi-Zoccai GG, Crea F (2006) Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients. Eur Heart J 27:519\u2013526","journal-title":"Eur Heart J"},{"key":"17_CR9","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1055\/s-2005-869523","volume":"31","author":"P Savi","year":"2005","unstructured":"Savi P, Herbert J-M (2005) Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin Thromb Hemost 31:195\u2013204","journal-title":"Semin Thromb Hemost"},{"key":"17_CR10","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1055\/s-0038-1657701","volume":"78","author":"J Himber","year":"1997","unstructured":"Himber J, Kirchhofer D, Riederer M, Tschopp TB, Steiner B, Roux SP (1997) Dissociation of antithrombotic effect and bleeding time prolongation in rabbits by inhibiting tissue factor function. Thromb Hemost 78:1142\u20131149","journal-title":"Thromb Hemost"},{"key":"17_CR11","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1055\/s-0038-1642443","volume":"71","author":"S Hollenbach","year":"1994","unstructured":"Hollenbach S, Sinha U, Lin P-H et al (1994) A comparative study of prothrombinase and thrombin inhibitors in a novel rabbit model of non-occlusive deep vein thrombosis. Thromb Hemost 71:357\u2013362","journal-title":"Thromb Hemost"},{"key":"17_CR12","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1161\/hq0302.105375","volume":"22","author":"CJ Refino","year":"2002","unstructured":"Refino CJ, Jeet S, DeGuzman L, Bunting S, Kirchhofer D (2002) A human antibody that inhibits factor IX\/IXa function potently inhibits arterial thrombosis without increasing bleeding. Arterioscler Thromb Vasc Biol 22:517\u2013522","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"17_CR13","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1124\/jpet.102.040089","volume":"303","author":"PC Wong","year":"2002","unstructured":"Wong PC, Crain EJ, Watson CA et al (2002) Nonpeptide factor Xa inhibitors III: effects of DPC423, an orally-active pyrazole antithrombotic agent, on arterial thrombosis in rabbits. J Pharmacol Exp Ther 303:993\u20131000","journal-title":"J Pharmacol Exp Ther"},{"key":"17_CR14","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/00005344-199808000-00001","volume":"32","author":"SA Mousa","year":"1998","unstructured":"Mousa SA, Olson RE, Bozarth JM et al (1998) Oral antiplatelet efficacy and specificity of a novel nonpeptide platelet GPIIb\/IIIa receptor antagonist, DMP 802. J Cardiovasc Pharmacol 32:169\u2013176","journal-title":"J Cardiovasc Pharmacol"},{"key":"17_CR15","first-page":"111","volume":"102","author":"MR Lassen","year":"2003","unstructured":"Lassen MR, Davidson BL, Gallus A, Pineo G, Ansell J, Deitchman D (2003) A phase II randomized, double-blind, five-arm, parallel-group, dose-response study of a new oral directly-acting factor Xa inhibitor, razaxaban, for the prevention of deep vein thrombosis in knee replacement surgery\u2014on behalf of the razaxaban investigators. Blood 102:111 (Abs 41)","journal-title":"Blood"},{"key":"17_CR16","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1182\/blood.V106.11.185.185","volume":"106","author":"G Agnelli","year":"2005","unstructured":"Agnelli G, Haas SK, Krueger KA, Bedding AW, Brandt JT (2005) A Phase II study of the safety and efficacy of a novel oral fXa inhibitor (LY517717) for the prevention of venous thromboembolism following TKR or THR. Blood 106:185 (Abs 278)","journal-title":"Blood"},{"key":"17_CR17","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1111\/j.1538-7836.2005.01602.x","volume":"3","author":"AG Turpie","year":"2005","unstructured":"Turpie AG, Fisher WD, Bauer KA et al (2005) BAY 59\u20137939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. J Thromb Hemost 3:2479\u20132486","journal-title":"J Thromb Hemost"},{"issue":"4, Suppl A","key":"17_CR18","first-page":"A288","volume":"47","author":"MU Zafar","year":"2004","unstructured":"Zafar MU, Gaztanaga J, Velez M et al (2004) A phase-I study to assess the antithrombotic properties of DU-176b: an orally active direct factor-Xa inhibitor. J Am Coll Cardio 47(4, Suppl A):A288 (Abs 908\u2013161)","journal-title":"J Am Coll Cardio"},{"issue":"5, Suppl 2","key":"17_CR19","doi-asserted-by":"publisher","first-page":"A443","DOI":"10.1016\/S0735-1097(04)91866-9","volume":"43","author":"MU Zafar","year":"2004","unstructured":"Zafar MU, Viles-Gonzalez J, Valdiviezo C et al (2004) Tissue factor pathway inhibition, a new antithrombotic strategy: phase-II study of a novel, oral factor Xa inhibitor. J Am Coll Cardio 43(5, Suppl 2):A443 (Abs 1007\u2013173)","journal-title":"J Am Coll Cardio"},{"key":"17_CR20","doi-asserted-by":"publisher","first-page":"151","DOI":"10.2174\/1568026013395380","volume":"1","author":"RJ Leadley Jr","year":"2001","unstructured":"Leadley RJ Jr (2001) Coagulation factor Xa inhibition: biological background and rationale. Curr Topics Med Chem 1:151\u2013159","journal-title":"Curr Topics Med Chem"},{"key":"17_CR21","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.thromres.2005.11.015","volume":"118","author":"HJ Daykin","year":"2006","unstructured":"Daykin HJ, Sturgeon SA, Jones C, Wright CE (2006) Arterial antithrombotic effects of aspirin, heparin, enoxaparin and clopidogrel alone, or in combination, in the rat. Thromb Res 118:755\u2013762","journal-title":"Thromb Res"},{"key":"17_CR22","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1161\/01.ATV.19.10.2554","volume":"19","author":"GZ Feuerstein","year":"1999","unstructured":"Feuerstein GZ, Patel A, Toomey JR et al (1999) Antithrombotic efficacy of a novel murine antihuman factor IX antibody in rats. Arterioscler Thromb Vasc Biol 19:2554\u20132562","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"17_CR23","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1097\/01.fjc.0000179000.93154.e0","volume":"46","author":"TT Hong","year":"2005","unstructured":"Hong TT, Huang J, Driscoll E, Lucchesi BR (2005) The antithrombotic effect of melagatran in combination with clopidogrel and\/or aspirin (carotid artery primary thrombosis study). J Cardiovasc Pharmacol 46:526\u2013533","journal-title":"J Cardiovasc Pharmacol"},{"key":"17_CR24","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1124\/jpet.103.059873","volume":"309","author":"J Lorrain","year":"2004","unstructured":"Lorrain J, Lechaire I, Gauffeny C et al (2004) Effects of SanOrg123781A, a synthetic hexadecasaccharide, in a mouse model of electrically induced carotid artery injury: synergism with the antiplatelet agent clopidogrel. J Pharmacol Exp Ther 309:235\u2013240","journal-title":"J Pharmacol Exp Ther"},{"key":"17_CR25","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1053\/euhj.2000.3234","volume":"23","author":"JW Eikelboom","year":"2002","unstructured":"Eikelboom JW, Weitz JI, Budaj A et al (2002) Clopidogrel does not suppress blood markers of coagulation activation in aspirin-treated patients with non-ST-elevation acute coronary syndromes. Eur Heart J 23:1771\u20131779","journal-title":"Eur Heart J"},{"key":"17_CR26","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1182\/blood.V80.8.2006.2006","volume":"80","author":"A Szczeklik","year":"1992","unstructured":"Szczeklik A, Krzanowski M, Gora P, Radwan J (1992) Antiplatelet drugs and generation of thrombin in clotting blood. Blood 80:2006\u20132011","journal-title":"Blood"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-007-0017-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-007-0017-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-007-0017-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-007-0017-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T01:04:12Z","timestamp":1652835852000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-007-0017-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2,24]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,8]]}},"alternative-id":["17"],"URL":"https:\/\/doi.org\/10.1007\/s11239-007-0017-9","relation":{},"ISSN":["0929-5305","1573-742X"],"issn-type":[{"value":"0929-5305","type":"print"},{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,2,24]]},"assertion":[{"value":"3 December 2006","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2007","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2007","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}